About Fascin-2
Fascin-2 (FSCN2) is a protein
from Homo sapiens identified by UniProt accession
O14926, 492 residues long.
MolForge cross-references it against 0 known binders and
134 disease associations.
Target properties
| Protein name | Fascin-2 |
| UniProt accession | O14926 |
| Gene | FSCN2 |
| Organism | Homo sapiens |
| Length | 492 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (134)
Diseases linked to this target (Open Targets).
- retinitis pigmentosa · score 0.49
- Retinal dystrophy · score 0.39
- macular degeneration · score 0.33
- hearing loss · score 0.26
- age-related hearing impairment · score 0.22
- serum gamma-glutamyl transferase measurement · score 0.18
- Meniere disease · score 0.16
- Leber congenital amaurosis · score 0.13
- aspartate aminotransferase to alanine aminotransferase ratio · score 0.09
- sex hormone-binding globulin measurement · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O14926-F1 | alphafold | PREDICTED | 93.63 | — |
Amino-acid sequence (492 residues)
MPTNGLHQVL KIQFGLVNDT DRYLTAESFG FKVNASAPSL KRKQTWVLEP DPGQGTAVLL RSSHLGRYLS AEEDGRVACE AEQPGRDCRF LVLPQPDGRW VLRSEPHGRF FGGTEDQLSC FATAVSPAEL WTVHLAIHPQ AHLLSVSRRR YVHLCPREDE MAADGDKPWG VDALLTLIFR SRRYCLKSCD SRYLRSDGRL VWEPEPRACY TLEFKAGKLA FKDCDGHYLA PVGPAGTLKA GRNTRPGKDE LFDLEESHPQ VVLVAANHRY VSVRQGVNVS ANQDDELDHE TFLMQIDQET KKCTFYSSTG GYWTLVTHGG IHATATQVSA NTMFEMEWRG RRVALKASNG RYVCMKKNGQ LAAISDFVGK DEEFTLKLIN RPILVLRGLD GFVCHHRGSN QLDTNRSVYD VFHLSFSDGA YRIRGRDGGF WYTGSHGSVC SDGERAEDFV FEFRERGRLA IRARSGKYLR GGASGLLRAD ADAPAGTALW EY
Explore Fascin-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets